Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.17
Views: 2556

Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA

Dr Manier speaks with ecancer at the 2017 ASH annual meeting about how next generation sequencing of smoldering multiple myeloma patients can identify genomic alterations associated with high-risk smoldering multiple myeloma vs low-risk smoldering multiple myeloma through different parameters such as mutation load, somatic mutations, and somatic copy number aberrations.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.  

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation